TY - JOUR
T1 - Interferon-β interferes with the proliferation but not with the cytokine secretion of myelin basic protein-specific, T-helper type 1 lymphocytes
AU - Pette, M.
AU - Pette, D. F.
AU - Muraro, P. A.
AU - Farnon, E.
AU - Martin, R.
AU - McFarland, H. F.
PY - 1997/8
Y1 - 1997/8
N2 - Interferon-β (IFN-β) has beneficial effects on the frequency and severity of relapses, as well as on disease progression in patients suffering from relapsing-remitting MS. Its mode of action, however, is not completely understood. Previous studies on T-lymphocyte bulk cultures and T-lymphocyte lines with specificity for different antigens suggested that the drug might partially act via suppression of T-cell proliferation and secretion of proinflammatory cytokines like interferon-γ (IFN-γ) and/or tumor necrosis factor-α (TNF-α). In this study we investigated the effects of human recombinant IFN-β(1b) on proliferation, interleukin 2 (IL-2) receptor (IL- 2R) α-chain upregulation, and cytokine and chemokine secretion of myelin basic protein-reactive, MS patient-derived T-cell clones secreting T-helper type 1 (Th1) cytokines. IFN-β partially suppressed both antigen- and IL-2- driven proliferation of these cells without affecting the expression of either IL-2 or IL-2R α-chain. There was no inhibitory effect on the secretion of IFN-γ, TNF-α, and macrophage inflammatory protein (MIP)-1α, but release was rather slightly enhanced. In conclusion, while IFN-β does reduce proliferation of Th1-like, MBP-specific T cells in vitro, the drug does not result in overall dysfunction of these cells. Therefore, the effect of IFN-β on MS may not depend on a primary inhibition of potentially encephalitogenic T lymphocytes.
AB - Interferon-β (IFN-β) has beneficial effects on the frequency and severity of relapses, as well as on disease progression in patients suffering from relapsing-remitting MS. Its mode of action, however, is not completely understood. Previous studies on T-lymphocyte bulk cultures and T-lymphocyte lines with specificity for different antigens suggested that the drug might partially act via suppression of T-cell proliferation and secretion of proinflammatory cytokines like interferon-γ (IFN-γ) and/or tumor necrosis factor-α (TNF-α). In this study we investigated the effects of human recombinant IFN-β(1b) on proliferation, interleukin 2 (IL-2) receptor (IL- 2R) α-chain upregulation, and cytokine and chemokine secretion of myelin basic protein-reactive, MS patient-derived T-cell clones secreting T-helper type 1 (Th1) cytokines. IFN-β partially suppressed both antigen- and IL-2- driven proliferation of these cells without affecting the expression of either IL-2 or IL-2R α-chain. There was no inhibitory effect on the secretion of IFN-γ, TNF-α, and macrophage inflammatory protein (MIP)-1α, but release was rather slightly enhanced. In conclusion, while IFN-β does reduce proliferation of Th1-like, MBP-specific T cells in vitro, the drug does not result in overall dysfunction of these cells. Therefore, the effect of IFN-β on MS may not depend on a primary inhibition of potentially encephalitogenic T lymphocytes.
UR - http://www.scopus.com/inward/record.url?scp=0030864154&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030864154&partnerID=8YFLogxK
M3 - Article
C2 - 9270566
AN - SCOPUS:0030864154
SN - 0028-3878
VL - 49
SP - 385
EP - 392
JO - Neurology
JF - Neurology
IS - 2
ER -